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ABSTRACT 
Parkinson’s disease is a neurodegenerative disorder characterized by Lewy bodies and neurites 
composed mainly of the presynaptic protein α-Synuclein. Frequently, Lewy bodies and neurites are 
identified in the gut of Parkinson’s disease patients and may underlie associated gastrointestinal 
dysfunctions. We recently reported selective expression of α-Synuclein in the axons of cholinergic 
neurons in the guinea pig and human distal gut; however, it is not clear whether asynuclein 
expression varies along the gut, nor how closely expression is associated with other synaptic 
proteins. We used multiple-labeling immunohistochemistry to quantify which neurons in the guinea 
pig ileum expressed α-Synuclein, cysteine string protein-a (CSPa), synaptophysin, synaptotagmin-1, 
or synaptobrevin-2 in their axons. Among the 10 neurochemically defined axonal populations, a 
significantly greater proportion of vesicular acetylcholine transporter-immunoreactive (VAChT-IR) 
varicosities (80% 6 1.7%, n . 4, P < 0.001) contained α-Synuclein immunoreactivity, and a 
significantly greater proportion of α-Synuclein-IR axons also contained VAChT immunoreactivity 
(78% 6 1.3%, n . 4) compared with any of the other nine populations (P < 0.001). Among 
synaptophysin-, synaptotagmin-1-, synaptobrevin-2-, and CSPa-IR varicosities, 98% 6 0.7%, 96% 6 
0.7%, 88% 6 1.6%, and 85% 6 2.9% (n . 4) contained α-Synuclein immunoreactivity, respectively. 
Among α-Synuclein-IR varicosities, 96% 6 0.9%, 99% 6 0.6%, 83% 6 1.9%, and 87% 6 2.3% (n . 
4) contained synaptophysin-, synaptotagmin-1-, synaptobrevin-2-, and CSPa immunoreactivity, 
respectively. We report a close association between the expression of α-Synuclein and the 
expression of other synaptic proteins in cholinergic axons in the guinea pig ileum. Selective 
expression of α-Synuclein may relate to the neurotransmitter system utilized and predispose 
cholinergic enteric neurons to degeneration in Parkinson’s disease.  
 
INTRODUCTION 
α-Synuclein is a neuronal protein of 140 amino acids, localized to presynaptic terminals. Although 
the protein is expressed widely throughout the nervous system, it is far from ubiquitous in 
presynaptic terminals (Maroteaux et al., 1988; Solano et al., 2000; Braak et al., 2000; Li et al., 
2002; Phillips et al., 2008; Sharrad et al., 2012a), but its selective expression and functional 
significance have not been examined in detail. α-Synuclein functions as a chaperone in the synaptic 
vesicle cycle for the soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) protein synaptobrevin-2 (Burre et al., 2010). During neurotransmitter release, the vesicle- 
SNARE synaptobrevin-2 and the transmembrane-SNAREs syntaxin and synaptosome-associated 
protein of 25 kDa (SNAP-25) assemble into SNARE complexes between the vesicle and the 
presynaptic membrane to facilitate exocytosis of neurotransmitter (Sudhof, 2004; Jahn and Scheller, 
2006; Sudhof and Rothman, 2009). Together, α-Synuclein and cysteine string protein-a (CSPa) 
chaperone and maintain the levels of synaptobrevin-2 and SNAP-25, respectively, in presynaptic 
terminals (Burre et al., 2010; Sharma et al., 2011a,b). Loss of the chaperone activity of α-Synuclein 
or CSPa exacerbates misfolding and depletion of synaptobrevin-2 or SNAP-25, respectively, from 
presynaptic terminals. In turn, this leads to a deficit in SNARE-complex assembly and 
neurodegeneration (Fernandez- Chacon et al., 2004; Chandra et al., 2005; Schmitz et al., 2006; 
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Burre et al., 2010; Greten-Harrison et al., 2010; Sharma et al., 2011a,b). If the chaperone activity of 
these two proteins is perturbed, presynaptic terminals that turn over synaptic vesicles at high rates 
become particularly susceptible to deleterious events associated with neurotransmitter release 
(Schmitz et al., 2006; Burre et al., 2010; Sharma et al., 2011b). These observations may be relevant 
to neurodegenerative diseases that implicate these chaperone proteins (Spillantini and Goedert, 
2000; Noskova et al., 2011), because evidence points toward presynaptic terminals as being the 
earliest sites disturbed (Wishart et al., 2006; Kramer and Schulz-Schaeffer, 2007; Scheff et al., 
2007; Gray et al., 2009; Milnerwood and Raymond, 2010; Schulz-Schaeffer, 2010; Waites and 
Garner, 2011).  
 
Parkinson’s disease (PD) is associated with the widespread loss of select classes of neurons and 
their connections throughout the nervous system. The specific hallmark pathology of sporadic PD is 
the presence of Lewy bodies and neurites: these comprise abnormal protein aggregates in cell 
bodies and axons at sites of neurodegeneration (Jellinger, 1986). The major constituent of Lewy 
pathology is thought to be aggregated α-Synuclein, suggesting that the protein is involved in the 
disease pathogenesis (Spillantini et al., 1997). In support of this notion, three mutations in SNCA, 
the gene encoding asynuclein (A53T, A30P, and E46K; Polymeropoulos et al., 1997; Kruger et al., 
1998; Zarranz et al., 2004), as well as gene duplications and triplications (Singleton et al., 2003; 
Nishioka et al., 2006), can cause PD. Additionally, genome- wide association studies have 
identified SNCA as the gene most broadly relevant to sporadic PD (Satake et al., 2009; Simon-
Sanchez et al., 2009).  
 
Although PD is best known as a disease involving the central nervous system, the peripheral 
nervous system, including the enteric nervous system, is also consistently affected (Wakabayashi 
and Takahashi, 1997; Beach et al., 2009). Frequently, Lewy pathology is identified in the distal gut 
of patients diagnosed with PD but is absent from the distal gut of age-matched controls 
(Wakabayashi et al., 1988; Lebouvier et al., 2010). We recently reported selective expression of α-
Synuclein in the axons of cholinergic enteric neurons in the guinea pig and human distal bowel 
(Sharrad et al., 2012a). It is well documented that α-Synuclein expression varies throughout the 
central nervous system (Solano et al., 2000), but whether its expression differs between regions of 
gut is not known. Given that α-Synuclein functions in the synaptic vesicle cycle, it is possibly 
associated with expression of particular synaptic proteins; however, this has not yet been directly 
investigated.  
 
This study quantifies the coexistence of α-Synuclein with other synaptic proteins in axons of enteric 
neuronal populations in the guinea pig ileum. As previously reported for guinea pig rectum, 
expression of α-Synuclein was closely related to expression of the cholinergic marker vesicular 
acetylcholine transporter (VAChT) in enteric axons. This study shows that α-Synuclein and VAChT 
coexpression was also associated with expression of the synaptic vesicle proteins, synaptobrevin-2, 
synaptophysin, and synaptotagmin-1 and the SNAP-25 chaperone, CSPa, in axons. We speculate 
that selective expression of α-Synuclein in classes of cholinergic enteric neurons could be related to 
their high rate of synaptic vesicle turnover and predispose them to degeneration in PD. 
 
MATERIALS AND METHODS  
Guinea pig tissue collection and processing for immunohistochemistry 
 
Adult guinea-pigs of either sex (weight 230–360 g) were stunned and killed by exsanguination, in a 
manner approved by the Animal Welfare Committee of Flinders University, South Australia. 
Animals were opened along the ventral midline, and the ileum was removed, intestinal contents 
were flushed, and the preparation was placed in Krebs solution (118 mM NaCl, 4.75 mM KCl, 1.0 
mM NaH2PO4, 25 mM NaHCO3, 1.2 mM MgSO4, 11.1 mM Dglucose, 2.5 mM CaCl2). Segments 
of ileum were pinned in a Sylgard-lined petri dish (Dow Corning, Midland, MI) filled with 
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phosphate-buffered saline (PBS; 0.15 M NaCl, 0.01 M NaH2PO4, pH 7.2), opened longitudinally 
along the mesenteric border, and stretched. The wholemount was immersed in modified Zamboni’s 
fixative (2% formaldehyde, 15% saturated picric acid in 0.1 M phosphate buffer, pH 7.0) for 
approximately 24 hours at 4_C. It was then cleared with three washes of 100% dimethyl sulfoxide 
(DMSO), and stored in PBS at 4_C. The mucosa, submucosa, and circular muscle layers were 
removed via sharp dissection, leaving the myenteric plexus and longitudinal muscle intact. 
 
Human brain tissue collection 
Fresh human neocortical tissue was obtained from the South Australian Brain Bank. Brains were 
dissected at autopsy, and half of the brain was immersion fixed for histological analysis and the 
other half snap frozen in dry ice powder and stored at _70_C for biochemical analysis. Brain tissue 




Preparations of myenteric plexus and longitudinal muscle, or strips of circular muscle, were cut into 
pieces approximately 5–10 mm square and incubated with antisera against different combinations 
of markers (Table 1) at room temperature for 2 days. Preparations were then rinsed three times in 
PBS and incubated with secondary antibodies (Table 2) for 4 hours at room temperature. After a 
final rinse with PBS, preparations were equilibrated with 50%, 70%, and 100% carbonate-buffered 
glycerol and mounted in 100% carbonate-buffered glycerol (pH 8.6). All antibodies were diluted in 
0.1 M PBS (0.3 M NaCl) containing 0.1% sodium azide. Controls for double labeling were 
performed by omitting one or more primary antibodies from the procedure and by ensuring that all 
combinations of primary and secondary antisera were free of cross-reactivity. 
 
Western blot 
Fresh human neocortical tissue was homogenized in RIPA buffer (50 mM HEPES, 50 mM NaCl, 
0.1% sodium dodecyl sulfate [SDS], 1% NP-40 nonionic detergent, 2 mM EDTA, 2 mM EGTA, 1 
mM phenylmethylsulfonyl fluoride, 5 lg/ml leupeptin, and 10 lg/ml aprotinin). Twenty micrograms 
of total protein was loaded and separated in 4–12% SDS-PAGE gel and subsequently transferred to 
polyvinylidene fluoride (PVDF), blocked with 5% skim milk in Tris-buffered saline (150 mM NaCl, 
0.1% Tween 20, 20 mM Tris, pH 7.4), and probed with the primary antisera against synaptobrevin-
2 (1:2,000; for details see Table 1) overnight at 4_C. This was followed by horseradish peroxidase- 
coupled secondary antisera (1:10,000) for 1 hour, washing, and placement over 1 ml ECF substrate 
(Super- Signal; Thermo, Rockford, IL) for 5 minutes, then scanned using the ImageQuant LAS 





Two polyclonal antibodies against α-Synuclein raised in sheep and rabbit were used. The rabbit 
polyclonal antibody (Rb2-190303-WS), generated by Dr. Wei-Ping Gai, recognizes a 19-kDA band 
on Western blots of human cerebral cortex extracts at the molecular weight of α-Synuclein and does 
not cross-react with b-synuclein. Staining is abolished after incubation with 20 lg/ml of the cognate 
peptide (Jakes et al., 1994). Staining with the sheep polyclonal antibody against α-Synuclein, also 
generated by Dr. Wei-Ping Gai, is abolished by preabsorption with the immunizing antigen and 
recombinant human α-Synuclein (Gai et al., 1999). The sheep antiserum gave identical labeling, to 
the level of single varicosities, when double- labeled with the rabbit antiserum in the present study 




The 5-hydroxytryptamine (5-HT) antibody (Incstar, Hudson, WI; catalog No. 20079; lot No. 
108072) was a polyclonal antiserum raised in goat against 5-HT conjugated to bovine serum 
albumin. Staining with this antibody was abolished by incubation of the diluted antibody with 100 
lg of 5-HT/BSA conjugate (manufacturer’s data sheet). 
 
Calbindin. 
The calbindin antibody (SWant, Belinzona, Switzerland; catalog No. CB38; lot No. 5.5) was a 
polyclonal raised in rabbit against recombinant rat calbindin D-28k. It recognizes a single band of 
approximately 27–28 kDa on Western blots of mouse brain homogenate, corresponding to the 
protein’s molecular weight (manufacturer’s data sheet; Ng et al., 1996). The antibody does not stain 
the brain of calbindin D-28k knockout mice (manufacturer’s data sheet). Staining is abolished by 
preabsorption with 1 lM recombinant rat calbindin D-28k (Reiche et al., 1999). 
 
Calretinin. 
The calretinin antibody (Rogers; catalog No. Ab-6C), generously provided by Dr. J.H. Rogers of 
Cambridge University, was a polyclonal raised in rabbit against chick calretinin– b-galactosidase 
fusion protein, containing putative calcium binding domains III and IV (Rogers, 1989a,b). The 
antibody stains a single 29 kDa band in rat cerebellum homogenates on Western blots (Bell et al., 
2005), corresponding to the protein’s molecular weight (Rogers, 1989b). 
 
Calcitonin gene-related peptide. 
The calcitonin gene-related peptide (CGRP) antibody (Peninsula, Belmont, CA; catalog No. 
IHC6006; lot No. 040826-2) was a polyclonal raised in rabbit against rat CGRP (peptide sequence 
HSCATATCVTHRLAGLLSRSGGVVKNNFVPTNVGSEAF- NH2). It recognized a single band 
of approximately 14 kDa, corresponding to CGRP’s molecular weight, on Western blots of horse 
ileum homogenates (Russo et al., 2010). Preabsorption of the diluted antibody with the immunogen 
abolishes staining in horse spinal cord, dorsal root ganglia, and intestine (Domeneghini et al., 2004). 
 
Cysteine string protein-a. 
The CSPa antibody (CSPa; Synaptic Systems, Goettingen, Germany; catalog No. 154 003) was a 
polyclonal raised in rabbit against a synthetic peptide of C-terminal rat CSPa (peptide sequence 
TQLTADSHPSYHTDGFN) coupled to keyhole limpet hemocyanin via an added Cterminal 
cysteine residue. The antibody recognizes a single band of expected size on Western blots of chick 
retina and brain (Wahlin et al., 2008) Neuronal nitric oxide synthase. The neuronal nitric oxide 
synthase (nNOS) antibody (Emson; catalog No. K205), generously provided by Dr. P. Emson, was 
a polyclonal raised in sheep against recombinant rat brain nNOS. It labels an intense band at 160 
kDa (theoretical molecular weight of 160 kDa) and a fainter band at 40 kDA on Western blots of 
guinea-pig inferior mesenteric ganglion and pelvic ganglia (Olsson et al., 2006). 
 
Somatostatin. 
The somatostatin antibody (SOM; Brown; catalog No. Soma 8) was a monoclonal raised in mice 
against somatostatin- 14 conjugated to keyhole limpet hemocyanin using carbodiimide (Buchan et 
al., 1985). Preabsorption of the diluted antibody with 100 lg/ml somatostatin-14 abolished labeling 
in the rat amygdala (Muller et al., 2007). 
 
Substance P. 
The substance P (SP) antibody (Chemicon, Temecula, CA; catalog No. MAB356; lot No. 
LV1362790) was a monoclonal raised in rats against SP conjugated to bovine serum albumin with 
carbodiimide (Cuello et al., 1979). The specificity of the antibody for SP has been validated by 
radioimmunoassay (Hegarty et al., 2010). Preabsorption of the antibody with 200 lg/ml of the SP 




The synaptobrevin-2 antibody was a polyclonal raised in rabbit against human synaptobrevin-2 
residues 31– 44 (peptide sequence: RRLQQTQAQVDEVV) coupled to keyhole limpet hemocyanin 
via an added C-terminal cysteine residue. The antibody labels a single band at 17 kDa on Western 
blots of human brain homogenate (Fig. 1). 
 
Synaptophysin. 
The synaptophysin antibody (clone SY38; Boehringer, Indianapolis, IN) was a mouse monoclonal 
raised against presynaptic vesicles from bovine brain. The antibody labels a single band at 
approximately 38 kDa on Western blots of rat brain lysate, and labeling is abolished after 
preabsorption of the antibody with extract from purified rat brain presynaptic vesicles (Belichenko 
et al., 2009). 
 
Synaptotagmin-1. 
The synaptotagmin-1 antibody (Transduction Labs, Lexington KY; catalog No. S39520) was a 
mouse monoclonal raised against amino acids 72–223 of rat synaptotagmin- 1. The antibody labels 
a single band at 65 kDa on Western blots of rat brain lysates (manufacturer’s data sheet). 
 
Tyrosine hydroxylase. 
The tyrosine hydroxylase (TH) antibody (Diasorin, Saluggia, Italy; catalog No. 22941; lot No. 
136032) was a mouse monoclonal raised against TH extracted from rat PC12 cells. The antibody 
labels an intense band of 60 kDa (theoretical molecular weight of 56 kDa) and a faint band of 52–
54 kDa in Western blots of guinea-pig inferior mesenteric ganglion and pelvic ganglia (Olsson et al., 
2006). 
 
Vasoactive intestinal polypeptide. 
The vasoactive intestinal polypeptide (VIP) antibody (Chemicon; catalog No. AB1581, lot No. 
0611044826) was a polyclonal raised in sheep against synthetic peptide VIP (1–28) coupled to 
keyhole limpet hemocyanin with glutaraldehyde. Vesicular acetylcholine transporter. The vesicular 
acetylcholine transporter (VAChT) antibody (Phoenix Pharmaceuticals, Burlingame, CA; catalog 
No. HV007; lot No. 417149), was a polyclonal raised in goat against the C-terminal of human 
VAChT (peptide sequence CTRSRSERDVLLDEPPGLYDAVRLRE). Preabsorption of the 
antibody with 50 lm of the immunogen abolished labeling in the dentate gyrus of monkeys (Shamy 
et al., 2007). 
 
Microscopy and image analysis and processing 
Labeled nerves were examined on an Olympus (Tokyo, Japan) IX71 microscope equipped with 
epifluorescence and highly discriminating filters (Chroma Technology Co., Battledore, VT). Images 
were captured using a Roper Scientific (Coolsnap) camera and AnalySIS Imager 5.0 (Olympus-SIS, 
Mu¨nster, Germany) and saved as TIFF files. Matched micrographs of immunohistochemically 
labeled nerve structures were captured using a _40 objective water-immersion lens and displayed in 
ImageJ (NIH, Bethesda, MD) as a stack. By rapidly switching between matched micrographs, it 
was possible to determine accurately whether a single, randomly chosen, labeled varicosity 
contained the other marker (Olsson et al., 2004; Sharrad et al., 2012a). Varicosities were selected by 
moving the mouse cursor rapidly to a region of the ganglion that had not yet been sampled and 
choosing the closest, infocus varicosity, irrespective of size or intensity of labeling. This method 
will be referred to as the ‘‘cursorselected coordinate’’ method (Sharrad et al., 2012a). Varicosities 
that were out-of-focus or overlying intensely labeled nerve cell bodies or other structures were 
excluded. Five or ten varicosities were selected at widely separated sites in each ganglion, and 
either 20 or 10 stacks were examined, giving total counts of 100 varicosities in each of four guinea 
pigs. To analyze axons in the muscle layers, a transect line was drawn and the five varicosities 
closest to the line were quantified from 20 stacks, resulting in total counts of 100 varicosities in 
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each of the four animals. Both methods give results similar to quantification based on confocal 
microscopy but allow much larger samples (Sharrad et al., 2012a). Group data are expressed as 
percentage means (mean number of varicosities from a sample of 100) 6 SEM, with n referring to 
the number of animals. Figures were generated from gray-scale images adjusted for contrast and 
brightness in Adobe Photoshop CS5 and were cropped and resized to improve display of 
varicosities of interest. 
 
Statistical analysis 
All statistical analysis was performed in SPSS19 for PC (SPSS, Chicago, IL). One-way ANOVA 
with Tukey’s HSD test was used to compare the means of more than two samples. Differences were 




Reliability of α-Synuclein antisera to label varicosities in the enteric nervous system 
We first compared the reliability of the two α-Synuclein antisera to label varicosities in the enteric 
nervous system. Preparations of guinea-pig ileum double-labeled with both antisera to α-Synuclein 
revealed nearly complete coexistence in varicosities (sheep α-Synuclein./rabbit α-Synuclein.: 100% 
6 0.3%, n . 4; rabbit α-Synuclein./ sheep α-Synuclein.: 99% 6 0.4%, n . 4), suggesting that the 
antisera could be used interchangeably to reveal varicosities containing α-Synuclein. 
 
Coexistence of neuronal markers with asynuclein in varicosities in myenteric ganglia 
We quantified the coexistence of α-Synuclein with characterized markers of neuronal populations in 
myenteric ganglia of guinea-pig ileum (Costa et al., 1996; Fig. 2). Myenteric ganglia contain axons 
of enteric interneurons, intrinsic primary afferent neurons, and spinal afferent and sympathetic 
neurons. The combination of markers accounts for over 95% of nerve cell bodies in the myenteric 
plexus (Costa et al., 1996) and the axons of extrinsic spinal afferent (Gibbins et al., 1986) and 
sympathetic (Macrae et al., 1986) neurons. 
 
The proportion of varicosities in each neurochemically defined population that contained α-
Synuclein varied widely (Table 3). For example, just 6% 6 1.1% (n . 4) of SP-IR varicosities in 
myenteric ganglia were α-Synuclein-IR, but 45% 6 4.9% (n . 4) of NOS-IR varicosities were α-
Synuclein-IR. Among the 10 neurochemically defined populations of varicosities studied, a 
significantly greater proportion of VAChT-IR varicosities contained α-Synuclein immunoreactivity 
(80% 6 1.7%, n . 4) than any of the other populations studied (P < 0.001 in all cases, f . 82.633 and 
df . 9). We also quantified the coexistence of VAChT and TH immunoreactivity in varicosities in 
myenteric ganglia: 0% 6 0% (n . 4) of TH-IR varicosities were VAChT-IR. 
 
Coexistence of α-Synuclein with neuronal markers in varicosities in myenteric ganglia 
We also quantified the coexistence of α-Synuclein with markers of neuronal populations the other 
way around. That is, we quantified the proportion of α-Synuclein-IR varicosities that contained 
markers of neuronal populations. Again, the proportions varied greatly between populations (Table 
4). For example, α-Synuclein-IR varicosities rarely contained CGRP immunoreactivity (2% 6 1%, 
n . 4), but a moderate proportion contained NOS immunoreactivity (15% 6 2.3%, n . 4). However, a 
significantly greater proportion of α-Synuclein-IR varicosities contained VAChT immunoreactivity 
(78% 6 1.3%, n . 4) than any of the other nine markers of neuronal populations studied (P < 0.001 
in all cases, f . 272.325, df . 9). 
 
Coexistence of α-Synuclein with neuronal markers in varicosities in deep muscular plexus 
The deep muscular plexus contains axons of excitatory and inhibitory motorneurons that originate 
in the myenteric plexus and innervate the circular muscle layers (Wilson et al., 1987). The axons of 
excitatory and inhibitory motorneurons can be distinguished by VAChT immunoreactivity and 
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NOS or VIP immunoreactivity, respectively. In the deep muscular plexus, α-Synuclein was 
expressed in nearly all axons of excitatory cholinergic motorneurons, labeled by VAChT 
immunoreactivity, but was almost never expressed in the axons of inhibitory motorneurons, labeled 
by VIP or NOS immunoreactivity (Fig. 3, Table 5). Almost all α-Synuclein-IR varicosities were 
VAChT-IR; few were VIP-IR or NOS-IR (Table 6). 
 
Coexistence of α-Synuclein with neuronal markers in varicosities in tertiary plexus 
The tertiary plexus contains axons of excitatory and inhibitory motorneurons that originate in the 
myenteric plexus and innervate the longitudinal muscle layers. The axons of excitatory and 
inhibitory motorneurons can be distinguished by VAChT immunoreactivity vs. NOS or VIP 
immunoreactivity. As was observed in the deep muscular plexus, almost all VAChT-IR varicosities 
were α-Synuclein- IR (99% 6 0.4%, n . 4), and no VIP-IR varicosities were α-Synuclein-IR (0% 6 
0%, n . 4) in the tertiary plexus (Fig. 3). All α-Synuclein-IR varicosities were VAChT-IR (100% 6 
0.3%, n . 4), and few were VIP-IR (1% 6 0.3%, n . 4). 
 
Coexistence of α-Synuclein and VAChT with synaptic proteins in varicosities in myenteric 
ganglia 
The results indicate that α-Synuclein is preferentially localized with VAChT in varicosities in the 
myenteric plexus, deep muscular plexus, and tertiary plexus of guinea-pig ileum, similar to the 
guinea-pig rectum. VAChT is a synaptic vesicle membrane transporter that concentrates 
acetylcholine in vesicles for release as a neurotransmitter. For this reason, we tested whether α-
Synuclein might also be preferentially associated with other synaptic proteins. To do this, we 
quantified the coexistence of asynuclein and VAChT with the synaptic vesicle proteins 
synaptophysin, synaptotagmin-1, and synaptobrevin-2 and the SNAP-25 chaperone CSPa in 
varicosities in myenteric ganglia (Fig. 4).  
 
Labeling of the myenteric plexus with antisera against synaptophysin, synaptotagmin-1, 
synaptobrevin-2, or CSPa revealed high densities of labeled axonal varicosities, but not nerve cell 
bodies, within myenteric ganglia and internodal strands. Nearly all varicosities in myenteric ganglia 
that contained synaptophysin-, synaptotagmin- 1, synaptobrevin-2, or CSPa immunoreactivity also 
contained α-Synuclein immunoreactivity (Table 1). When we quantified coexistence the other way 
around, most asynuclein- IR varicosities were found to contain synaptophysin, synaptotagmin-1, 
synaptobrevin-2, and CSPa (Table 2). For myenteric ganglia, we observed that most varicosities 
that contain VAChT or α-Synuclein also contain the other protein (Table 1). Therefore, VAChT 
must be present in most varicosities that contain the synaptic proteins investigated, which we 
confirmed by quantifying the coexistence of VAChT with synaptophysin and synaptotagmin- 1 
both ways around (synaptotagmin-1./ VAChT.: 99% 6 0.6%; synaptophysin./VAChT.: 90% 6 
0.2%; VAChT./synaptotagmin-1.: 96% 6 0.7%; VAChT./synaptophysin.: 98% 6 0.6%, n . 4). 
Together these results indicate that, in myenteric ganglia, most varicosities that contain VAChT, α-
Synuclein, CSPa, synaptotagmin- 1, synaptophysin, or synaptobrevin-2 contain this full 
complement of synaptic proteins. 
 
Coexistence of α-Synuclein and VAChT with synaptic proteins in varicosities in deep 
muscular plexus 
The expression pattern of the synaptic proteins investigated in the myenteric plexus was very 
similar in the deep muscular plexus. When preparations of circular muscle labeled with various 
antisera were investigated, localization of immunoreactivity for synaptophysin, synaptotagmin- 1, 
synaptobrevin-2, and CSPa was restricted to bundles of axons of motorneurons, running parallel to 
the circular muscle layer (Figs. 5, 6). As was observed in myenteric ganglia, nearly all 
synaptophysin-, synaptotagmin- 1-, synaptobrevin-2-, and CSPa-IR varicosities contained α-
Synuclein (Table 5). Quantification of α-Synuclein with markers the other way around revealed that 
most α-Synuclein-IR varicosities also contained synaptophysin-, synaptotagmin-1, synaptobrevin-2, 
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and CSPa immunoreactivity (Table 6). Almost all varicosities in deep muscular plexus that contain 
VAChT or α-Synuclein contain the other protein (Tables 5, 6). This indicates that VAChT is 
present in all the α-Synuclein-IR varicosities that contain the synaptic proteins studied, and all 
varicosities containing these synaptic proteins also contain VAChT. This was confirmed directly for 
synaptophysin and synaptotagmin- 1 (synaptotagmin-1./VAChT.: 99% 6 0.3%; 
synaptophysin ./VAChT.: 92% 6 0.9%; VAChT./synaptotagmin- 1.: 99% 6 1.2%; 
VAChT./synaptophysin.: 98% 6 1.2%, n . 4). As was observed in myenteric ganglia, these results 
indicate that most varicosities in the deep muscular plexus that contain VAChT, α-Synuclein, CSPa, 




Enteric neurons in the myenteric plexus are arranged into complete neural circuits that give rise to 
the stereotyped reflexes and patterned motor behaviors of the gut. This is mediated by numerous 
neurotransmitters released by myenteric neurons, including small molecules such as acetylcholine, 
released from small clear synaptic vesicles, as well as peptides such as substance P and 
somatostatin, released from large dense-core vesicles. Transmitter release of small molecules and 
peptides from these two distinct vesicle classes is controlled by overlapping, but different, 
complements of synaptic proteins (Tandon et al., 1998; Morris et al., 2001, 2002). These contribute 
to different release kinetics following arrival of action potentials at presynaptic terminals (Verhage 
et al., 1991; Bruns and Jahn, 1995; Hokfelt et al., 2000; Harata et al., 2001; Ohnuma et al., 2001; 
Barg et al., 2002). In this study, we quantified the coexistence of α-Synuclein, and other synaptic 
proteins with markers of various neurotransmitter systems in the axons of myenteric neurons. 
Strikingly, the expression of the chaperones α-Synuclein and CSPa and the synaptic vesicle proteins 
synaptobrevin- 2, synaptophysin, and synaptotagmin-1 was restricted mostly to axons that were 
immunoreactive for VAChT. 
 
Selective expression of α-Synuclein in the enteric nervous system of the guinea pig ileum 
As has been previously reported for guinea pig rectum and human colon, α-Synuclein is expressed 
in most classes of enteric neurons. The exception is inhibitory noncholinergic motorneurons to the 
longitudinal and circular muscle layers, which nearly always lack α-Synuclein (Sharrad et al., 
2012a). Within each population, α-Synuclein is preferentially localized in varicosities that 
contained the cholinergic marker VAChT. In the guinea pig rectum, a small proportion of 
varicosities in SOM-IR or SP-IR populations contained measurable VAChT: these were the same 
varicosities that contained α-Synuclein (Sharrad et al., 2012a). Thus, it is likely that varicosities 
containing α-Synuclein that were labeled by markers other than VAChT in this study also contained 
VAChT. One exception to this pattern was in TH-IR varicosities, 32% of which contained α-
Synuclein in this study of guinea-pig ileum; these varicosities do not contain VAChT 
immunoreactivity. Interestingly, in the rectum, α-Synuclein was almost entirely absent from TH-IR 
varicosities (Sharrad et al., 2012a), indicating that α-Synuclein immunoreactivity varies between 
sympathetic neurons in celiac and superior mesenteric ganglia that innervate the ileum compared 
with sympathetic neurons in the inferior mesenteric ganglion and pelvic ganglia that innervate the 
rectum (Messenger and Furness, 1993; Olsson et al., 2006). The similar results of this study and our 
previous study from two distinct regions of gut suggest that selective expression of α-Synuclein in 
cholinergic neurons in the gut is not region specific. 
 
Discrepancies in the chemical coding of axons and cell bodies of myenteric neurons 
Nerve cells in the myenteric plexus of the guinea pig ileum have been divided into discrete 
functional classes distinguishable by their unique combinations of molecules and enzymes in their 
cell bodies (‘chemical coding’; Costa et al., 1996). Choline acetyltransferase (ChAT), a cholinergic 
marker, has been reported to be consistently co-localized with 5-hydroxytryptamine (5-HT) in 
interneuronal cell bodies (Steele et al., 1991). Therefore, the axons of these neurons would be 
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expected to contain both 5-HT and VAChT. However, only 34% 6 3% of 5-HTIR varicosities 
contained α-Synuclein immunoreactivity, but 80% 6 1.7% of VAChT-IR varicosities contained α-
Synuclein immunoreactivity. If all 5-HT-IR varicosities contained VAChT immunoreactivity, then 
closer to 80% of 5- HT-IR varicosities would be expected to contain α-Synuclein immunoreactivity. 
However, whether the chemical codes that distinguish the cell bodies of different functional classes 
of neurons also distinguish their axons has only been recently investigated. A recent study from our 
laboratory indicates that chemical codes that distinguish different classes of nerve cell bodies in the 
myenteric plexus of the guinea pig ileum often differ from chemical codes of their axons (Sharrad 
et al., 2012b). For example, only 29% 6 5% (n . 4) of 5-HT-IR varicosities contain VAChT 
immunoreactivity (Sharrad et al., 2012b). This discrepancy in the colocalization of cholinergic 
markers in cell bodies and axons was also observed for other markers, including calretinin, SP, and 
SOM. These observations indicate that care must be taken when extrapolating chemical codes 
established for cell bodies to axons. 
 
Selective expression of synaptic proteins in cholinergic axons that express α-Synuclein 
α-Synuclein is largely localized to the axons of neurons (Maroteaux et al., 1988). In presynaptic 
terminals, it chaperones synaptobrevin-2 and protects it against misfolding and subsequent 
depletion from presynaptic terminals, which would otherwise result in a deficit in SNARE-complex 
assembly (Burre et al., 2010). Although α-Synuclein plays an auxiliary role in the synaptic vesicle 
cycle, rather than being directly involved in vesicular function, it is particularly important in 
protecting terminals that turn over synaptic vesicles at high rates (Chandra et al., 2005; Greten-
Harrison et al., 2010; Burre et al., 2010). Enteric nerve terminals that express VAChT presumably 
release acetylcholine, which is a major fast neurotransmitter in the gut (Galligan et al., 2000). There 
was a close association between the presence of α-Synuclein and VAChT in these terminals and the 
expression of the synaptic vesicle proteins synaptobrevin-2, synaptophysin, and synaptotagmin- 1. 
This association held true for both terminals in myenteric ganglia, reflecting transmission from 
interneurons and intrinsic sensory neurons, and terminals in the deep muscular plexus, which 
contain axons of motorneurons that transmit to the circular muscle layers. In addition to the three 
synaptic vesicle proteins, CSPa, the chaperone of SNAP-25, was localized in the majority of these 
cholinergic terminals, together with α-Synuclein. Thus, CSPa is also likely to be closely associated 
with cholinergic axons. It should be noted that this discussion is limited to immunohistochemically 
detectable expression of proteins. We cannot rule out the possibility that nonimmunoreactive 
varicosities may express the investigated proteins at levels below the threshold for 
immunohistochemical detection. 
 
Functional implications of selective expression of α-Synuclein and synaptic proteins in 
cholinergic axons 
The selective expression of α-Synuclein, CSPa, synaptobrevin- 2, synaptophysin, and 
synaptotagmin-1 in particular classes of axons in the enteric nervous system may have functional 
implications. Most peptidergic varicosities in myenteric ganglia of the guinea pig ileum do not 
contain VAChT immunoreactivity (Sharrad et al., 2012b); a similar finding pertains to the rectum 
(Sharrad et al., 2012a). In turn, this suggests that large numbers of peptidergic varicosities lack 
synaptobrevin-2, synaptotagmin- 1, synaptophysin, and CSPa and do not require these proteins for 
normal synaptic function. Similarly, it has been previously reported that axons of peptide-
containing spinal afferent neurons that lack vesicular glutamate transporters do not express 
detectable SNAP-25, synaptophysin, synaptotagmin-1, or synaptobrevin-2 (Morris et al., 2005). 
The absence of key synaptic proteins from peptidergic axons has also been reported for autonomic 
ganglia (Gibbins et al., 2003) and glutamatergic ribbon synapses of the retina (Catsicas et al., 1992; 
Mandell et al., 1992; Brandstatter et al., 1996; Von Kriegstein et al., 1999). Despite the absence of 
these synaptic proteins, studies have shown functional transmission from peptidergic axons at 
neuroeffector junctions (Morris et al., 2001, 2002) and from glutamatergic ribbon synapses of inner 
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hair cells (Nouvian et al., 2011). The mechanisms and the proteins involved in this alternative 
release pathway have yet to be fully described.  
 
Synaptophysin regulates the readily releasable pool of synaptic vesicles, as well as synapse 
formation and plasticity (Janz et al., 1999; Daly et al., 2000; Tarsa and Goda, 2002). Its apparent 
absence in peptidergic varicosities lacking VAChT suggests that these functions may not operate in 
some enteric nerve terminals. Synaptotagmin-1 is the Ca2. sensor responsible for fast Ca2.-
triggered exocytosis of synaptic vesicles (Tang et al., 2006) and is required for synchronous release 
of fast neurotransmitters (Maximov and Sudhof, 2005). Its absence in noncholinergic peptidergic 
varicosities suggests that they release neuropeptides asynchronously, using a different Ca2. sensor 
mechanism. This is in accordance with functional studies showing that neuropeptide release is more 
closely related to bulk changes in intracellular calcium concentrations, accumulating from multiple 
action potentials invading the terminal (Verhage et al., 1991; Hokfelt et al., 2000). The present 
study also suggests that acetylcholine may be the only neurotransmitter in the enteric nervous 
system that undergoes Ca2.-triggered synchronous release.  
 
Synaptotagmin-1 permits sustained rounds of vesicular exocytosis via repetitive SNARE-complex 
assembly and disassembly in presynaptic terminals (Maximov and Sudhof, 2005; Tang et al., 2006). 
Activity of this nature is prone to cause misfolding and subsequent removal of both SNAP-25 and 
synaptobrevin-2 (Burre et al., 2010; Sharma et al., 2011b). CSPa and α-Synuclein are chaperone 
proteins that protect SNAP-25 and synaptobrevin-2 (Burre et al., 2010; Sharma et al., 2011b). We 
speculate that their association with functional cholinergic terminals in the enteric nervous system 
has evolved to allow rapid and repetitive synaptic activity, which would otherwise leave them 
vulnerable to activity-dependent misfolding of SNARE proteins. Presumably, noncholinergic 
peptidergic terminals are less susceptible to such damage, either because they use a different Ca2. 
sensor or because of their slower rate of vesicle turnover, and therefore do not require such 
protective mechanisms. Alternatively, they may utilize similar chaperone systems that have yet to 
be characterized. 
 
Enteric cholinergic neurons may be particularly vulnerable to neurodegeneration in PD 
In PD there is widespread loss of cholinergic neurons throughout the nervous system, including the 
dorsal motor nucleus of the vagus nerve (Gai et al., 1992), the pedunculopontine nucleus (Jellinger, 
1988), and the nucleus basalis of Meynert (Nakano and Hirano, 1984). This indicates that 
cholinergic neurons may be particularly vulnerable to damage in PD. Although enteric neurons 
show Lewy pathology in PD (Wakabayashi et al., 1988), it is not clear whether significant 
neurodegeneration occurs in the myenteric plexus. Furthermore, whether cholinergic neurons in the 
myenteric plexus are either targeted or spared by this neurodegenerative disease has not been 
investigated. The preferential expression of α-Synuclein in cholinergic neurons throughout the gut 
suggests that they may be susceptible in PD.  
 
In summary, we report that α-Synuclein is selectively expressed in the axons of cholinergic enteric 
neurons in the guinea-pig ileum. These results are similar to a recent report of selective expression 
of α-Synuclein in cholinergic enteric neurons in the guinea-pig rectum and human colon. The 
synaptic vesicle proteins synaptotagmin-1, synaptobrevin-2, and synaptophysin and vesicle-
associated protein CSPa are also selectively expressed in the same cholinergic enteric nerve 
terminals. These observations suggest that selective expression of α-Synuclein may be related to 
specific mechanisms of neurotransmitter release that require a package of synaptic machinery. 
Studies of cholinergic neurons in gut tissue may be useful in identifying how α-Synuclein is 
involved in PD. 
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FIGURE LEGENDS 
Figure  1.  Western  blot analysis  of synaptobrevin-2. Extracrs (20 μg) of protein from human neocortical 
tissue were transferred to poly-  vinylidene fluoride membranes and probed with antiserum against synap-  
tobrevin-2 (1:2,000; for details see Table 1). A single major band of  approximately 17 kDa was present 
(theoretical molecular weight 18 kDa). 
Figure  2.  Paired  fluorescence  images  of guinea  pig  ileum  myenteric  ganglia  immunohistochemically  
double  labeled  with antisera against a-synuclein and 5-HT (A,B), calretinin (D,E), VAChT (G,H), or VIP 
(J,K). Each pair of micrographs was screened to generate an overlay that contained varicosities labeled with 
both markers (C,F,I,L). Varicosities that contained immunoreactivity for a-synuclein and the other marker 
are indicated by arrows, and varicosities immunoreactive for the other marker alone are indicated by 
arrowheads. 5-HT, 5-hydroxy-  tryptamine; a-Syn, a-synuclein; VAChT, vesicular acetylcholine transporter; 
VIP, vasoactive intestinal polypeptide. Scale bars = 20μm  
Figure 3. Paired fluorescence images of varicose axons in the tertiary plexus (A–D) and deep 
muscular plexus (E–H) of the guinea pig ileum immunohistochemically double labeled with 
antisera against a-synuclein and NOS, VAChT, or VIP. Immunoreactivity for a-synuclein and 
VAChT coexisted in nearly all varicosities 
(indicated by arrows) in the deep muscular plexus (G,H) and tertiary plexus (A,B). 
Immunoreactivity for NOS or VIP rarely coexisted with a-synuclein in varicosities (indicated by 
arrowheads) in the deep muscular plexus (E,F) or tertiary plexus (C,D), respectively. a-Syn, a-
synuclein; NOS, nitric oxide synthase; VAChT, vesicular acetylcholine transporter; VIP, vasoactive 
intestinal polypeptide. Scale bars = 20μm 
 
Figure 4. Paired fluorescence images of guinea pig ileum myenteric ganglia double labeled with 
antisera against a-synuclein and either cysteine string protein-a (E,F) or synaptobrevin-2 (G,H) or 
VAChT and either synaptotagmin-1 (C,D) or synaptophysin (A,B). Varicosities that contained 
immunoreactivity for both markers are indicated by arrows. a-Syn, a-synuclein; CSPa, cysteine 
string protein-a; Synbrev-2, synaptobrevin-2; Synphys, synaptophysin; Syntag-1, synaptotagmin-1, 
VAChT, vesicular acetylcholine transporter. Scale bars = 20μm 
 
Figure 5. Paired fluorescence images of varicose axons in the deep muscular plexus of the guinea 
pig ileum immunohistochemically double labeled with antisera against VAChT and synaptophysin 
(C,D), synaptotagmin-1 (G,H), or a-synuclein and either 
synaptophysin (A,B) or synaptotagmin-1 (E,F). Varicosities that contained immunoreactivity for 
both markers are indicated by arrows. a-Syn, a-synuclein; Synphys, synaptophysin; Syntag-1, 
synaptotagmin-1; VAChT, vesicular acetylcholine transporter. Scale bars = 20μm 
 
Figure 6. Paired fluorescence images of varicose axons in the deep muscular plexus of the guinea 
pig ileum immunohistochemically double labeled with antisera against a-synuclein and either 
cysteine string protein-a (A,B) or synaptobrevin-2 (C,D). Varicosities that contained 
immunoreactivity for both markers are indicated by arrows. a-Syn, a-synuclein; CSPa, cysteine 
string protein-a; Synbrev-2, synaptobrevin-2. Scale bars = 20μm 
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